Valuation: LivaNova PLC

Market Cap 4.32B 3.8B 3.53B 3.25B 6.09B 418B 6.19B 42.19B 16.46B 204B 16.21B 15.86B 708B P/E 2026 *
28.2x
P/E 2027 * 24.4x
Enterprise Value 4.32B 3.8B 3.53B 3.25B 6.09B 418B 6.19B 42.19B 16.46B 204B 16.21B 15.86B 708B EV / Sales 2026 *
2.86x
EV / Sales 2027 * 2.67x
Free-Float
98.44%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 01/03/2024
Director of Finance/CFO 56 31/10/2020
Investor Relations Contact - 01/08/2022
Director TitleAgeSince
Director/Board Member 69 19/10/2015
Chairman 74 09/06/2021
Director/Board Member 62 18/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+0.64% - - 4.32B
+0.18%+1.94%-19.93%-11.85% 175B
+0.15%-1.85%-10.87%-7.81% 105B
+1.49%-0.95%+3.96%+58.40% 59.35B
-1.29%-2.76%+26.16%+54.51% 50.71B
-0.12%-4.35%-16.22%-42.24% 42.15B
+1.21%-8.47% - - 31.82B
-1.33%-9.62%-18.45%-46.03% 27.2B
-0.82%-1.92%+56.39%-5.79% 25.11B
+0.03%-4.74%-6.58%-9.24% 20.53B
Average -0.03%-3.42%+1.81%-1.26% 59.7B
Weighted average by Cap. +0.16%-1.51%-5.90%-0.07%

Financials

2026 *2027 *
Net sales 1.51B 1.33B 1.23B 1.13B 2.13B 146B 2.16B 14.73B 5.75B 71.23B 5.66B 5.54B 247B 1.61B 1.42B 1.32B 1.21B 2.28B 156B 2.32B 15.77B 6.15B 76.26B 6.06B 5.93B 265B
Net income 148M 131M 121M 112M 209M 14.37B 213M 1.45B 566M 7.01B 557M 545M 24.32B 179M 158M 147M 135M 253M 17.38B 257M 1.75B 684M 8.48B 674M 659M 29.41B
Net Debt - -
Logo LivaNova PLC
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA